PTLDs are a heterogeneous group of diseases ranging from reactive hyperplasia to malignant lymphoma that occur in patients after solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). PTLD can occur anywhere from weeks to decades after transplantation. Most are Epstein-Barr virus (EBV)-positive. In at least some instances, EBV gene expression appears to drive the lymphoproliferation in an environment of decreased cell-mediated immunity. Treatment may include reducing or changing immunosuppression, rituximab, adoptive T-cell therapy, or cytotoxic chemotherapy. Judicious selection of immunosuppressive agents, early intervention with rituximab, or utilization of EBVtargeted therapies is a promising prevention strategy.
- Epstein-Barr virus (EBV)
- Hematopoietic stem cell transplantation (HSCT)
- Immune suppression
- Posttransplantation lymphoproliferative disorders (PTLDs)
- Solid organ transplantation (SOT)
ASJC Scopus subject areas